Healio

FDA approves Qivigy for adults with primary humoral immunodeficiency

The FDA has approved Kedrion Biopharma’s Qivigy, a 10% IV immunoglobulin therapy, for treating adults who have primary ...
MPR

Qivigy Approved for Primary Humoral Immunodeficiency in Adults

Qivigy (immune globulin intravenous, human-kthm) is a ready-to-use, sterile, non-pyrogenic liquid solution of human immune globulin for IV administration.

Kedrion Biopharma Receives FDA Approval for QIVIGY® (Immune Globulin 10% IV) for treatment of Primary Humoral Immunodeficiency in Adults and confirms its plan …

Kedrion Biopharma announced today that it has received FDA approval for QIVIGY immune globulin intravenous (human)-kthm 10% ...
Pulmonology Advisor

Delaying Methotrexate Aids Pneumococcal Vaccine Response in Rheumatoid Arthritis

Delaying MTX initiation by 4 weeks after PCV13 vaccination significantly improved humoral responses in patients with RA, without compromising disease control.